Neurol. praxi. 2025;26(5):392-398 | DOI: 10.36290/neu.2025.013

Idiopathic inflammatory myopathies - new developments in treatment

MUDr. Heřman Mann, Ph.D.

Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha

The mainstay of treatment of all subtypes of idiopathic inflammatory myopathies, with the exception of inclusion body myositis, is pharmacotherapy with immunosuppressive and immunomodulatory agents. Different subtypes of the disease require different therapeutic approaches. Detection of myositis-specific autoantibodies, which are associated with a characteristic phenotype and response to therapy, plays an important role in deciding the choice of drug. It is always necessary to distinguish between true disease activity and damage, which cannot be influenced by pharmacotherapy. Given the increased incidence of malignancies, cancer screening is an important part of care. A number of clinical trials with new drugs have gradually expanded the therapeutic options in recent years. In particular, the results of T cell therapy with chimeric antigen receptor have attracted a lot of attention; single course of treatment has a potential to induce drug-free remission.

Keywords: idiopathic inflammatory myopathies, antisynthetase syndrome, immune mediated necrotizing myopathy, dermatomyositis, treatment.

Received: January 24, 2025; Revised: February 7, 2025; Accepted: February 8, 2025; Prepublished online: February 8, 2025; Published: November 6, 2025  Show citation